dplo report adj ebitda ahead consensu due better expect gross
margin due improv drug purchas sustain go forward
management also re-affirmed preliminari guidanc impli organ growth
y/i dplo look pois captur market growth specialti recent
acquir pbm asset given specialti capabl
better expect
compani report streetaccount thomson eikon cowen compani
dplo report revenu larg in-lin consensu adj
ebitda adj ep came ahead consensu
respect result higher expect gross margin better
expect gross margin due product mix favor result drug
management re-affirmed preliminari guidanc revenu
adj ebitda management also provid net incom attribut dplo
adj ep weight averag share tax rate
depreci amort addit dplo expect interest
expens
dplo specialti capabl uniqu posit pbm busi
specialti scale servic full portfolio limit distribut drug dplo
uniqu posit middle-market pbm space management see consider opportun
captur outsiz growth specialti leverag recent acquir pbm asset ldi
np specialti continu remain one greatest concern middle-market
employ notabl ldi np dplo access almost new drug
spent pbm target patient physician
pleas see page report import disclosur
larg posit dplo given macro tailwind specialti well uniqu
posit largest independ specialti pharmaci said given current
valuat remain sidelin attract entri point emerg specialti
drug trend expect remain high-teen driven price inflat
util drive robust pipelin specialti drug continu drive
util note bode well dplo substanti number drug
pipelin oncolog drug compani largest therapeut categori revenu
addit dplo focu success limit distribut drug allow
compani achiev market growth believ continu
 new indic exist drug
 addit new limit distribut panel
 updat renewal/sel season
 gross margin driven
better drug purchas
 adj ebitda margin
 top-lin growth rang due
better expect organ growth
 greater expect adj ebitda margin
strong oper leverag synergi
 top-lin growth teen due
greater expect declin hep
 gross margin
 lower expect adj ebitda margin
lack oper leverag lower
expect synergi
diplomat pharmaci largest independ specialti pharmaci unit state
compani focus specialti drug typic administ recur
basi treat patient complex chronic diseas requir special handl
administr part distribut process diplomat expertis across broad
rang high-growth specialti therapeut categori includ oncolog immunolog
hepat multipl sclerosi specialti infus therapi mani seriou and/
long-term condit compani servic includ assist complic
manag adher monitor diplomat partner lead biotechnolog
pharmaceut compani deliv custom support servic dispens new drug
updat estim price
rais adj ebitda estim
respect also rais price target base
revis dcf analysi impli share trade adj ebitda
estim current valuat
million expect per share data
compani report cowen compani
changevarianceneo good gross gross bp chang sell gener administr adjust adjust ebitda adjust adjust ebit interest chang fair valu redeem common shares- nm- termin exist stock redempt agreement- nm- equiti loss impair non-consolid entity- nm- restructur impair nm- non-recurring incom incom incom tax tax adjust net amort acquisition-rel intang conting consider impair non-consolid entity- nm- incom tax impact net incom alloc prefer shareholders- nm- net incom common dilut weight average common share adjust cowen
million except per share data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per share data
compani file cowen compani
good gross gross chang sell gener administr adjust ebitda adjust adjust ebit chang fair valu redeem common shares- termin exist stock redempt agreement- equiti loss impair non-consolid entity- restructur impair charge- non-recurring incom incom incom tax tax amort acquisition-rel intang conting consider impair non-consolid entity- incom tax impact net incom alloc prefer shareholders- gaap net incom common dilut weight average common share adjust gaap chang year-over-year net incom net end decemb cowen
million except per share data
compani file cowen compani
good gross gross chang sell gener administr adjust ebitda adjust adjust ebit restructur impair charge- non-recurring incom incom incom tax tax net amort acquisition-rel intang conting consider impair non-consolid entity- incom tax impact net incom alloc prefer shareholders- gaap net incom common dilut weight average common share adjust gaap chang year-over-year net incom net cowen
million
compani file cowen compani
asset account receiv defer incom prepaid expens current total current properti equip capit softwar intern use definite-liv intang asset invest non-consolid defer debt issuanc non-current total current liabil account borrow line credit- short-term debt includ current portion long-term accru expens conting compens total current long-term debt less current conting consider less current portion- defer incom non-current liabilities- mandatorili redeem common shares- total stockhold equiti common addit paid-in retain total dplo sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti cowen
million
compani file cowen compani
flow oper activ depreci chang fair valu conting conting consider payment- net provis doubt share-bas compens defer incom tax impair capit softwar intern use- loss gain sale dispos properti excess tax benefit relat share-bas awards- amort debt issuanc chang oper asset liabil account account payabl asset net cash oper acquisit expenditur capit softwar intern expenditur issuanc common purchas treasuri stock- proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end decemb cowen
million
compani file cowen compani
flow oper activ net adjust reconcil net incom net cash use oper activ depreci asset chang fair valu conting consideration- conting consider payment- net provis doubt share-bas compens equiti loss non-consolid defer incom tax expense- impair capit softwar intern use- loss gain sale dispos properti excess tax benefit relat share-bas awards- amort debt issuanc chang fair valu redeem common termin exist stock redempt agreement- certain expens paid notes- chang oper asset liabil account account payabl asset net cash use oper flow invest activ payment acquir busi net cash expenditur capit softwar intern expenditur properti capit invest loan non-consolid net cash use invest flow financ activ net payment line proce long-term debt- payment long-term proce public offer net transact costs- proce sale prefer stock net transact costs- payment made repurchas common stock- payment made repurchas stock options- proce issuanc stock upon stock option exercises- excess tax benefit relat share-bas awards- payment debt issuanc conting consider payments- sharehold net cash use provid financ net decreas increas cash equival begin period- equival end supplement disclosur cash flow inform paid paid incom taxes- year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ dplo
acquir significantli accret acquisit govern price control drug
suppli disrupt due relianc two supplier
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock diplomat pharmaci secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
